Natco Pharma’s marketing partner Alvogen has received the US Food and Drug Administration’s (USFDA) final nod for the abbreviated new drug application (ANDA) for nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg. These tablets are used to treat episodes of angina (chest pain) in people, who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart).
Citing IQVIA data, Natco Pharma said in a statement that nitroglycerin sublingual tablets had an annual sales of about $77.3 million in the U.S. market in 2018. Pfizer Pharmaceuticals markets the drug under its brand Nitrostat sublingual tablets in the same strengths.